[EN] 6-(4-HYDROXY-PHENYL)-1H-PYRAZOLO[3,4-B]PYRIDINE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS D'AMIDE DE L'ACIDE 6-(4-HYDROXY-PHÉNYL)-1H-PYRAZOLO[3,4-B]PYRIDINE-4-CARBOXYLIQUE EN TANT QU'INHIBITEURS DE KINASES
申请人:SANOFI SA
公开号:WO2013060636A1
公开(公告)日:2013-05-02
The present invention relates to 1 H-pyrazolo[3,4-b]pyridine compounds of the formula (I) in which R1, R2, R3 and R4 are defined as indicated below. The compounds of the formula I are protein kinase C (PKC) inhibitors, and are useful for the treatment of diseases associated with diabetes and diabetic complications, such as, diabetic nephropathy, diabetic neuropathy and diabetic retinopathy, for example. The invention furthermore relates to the use of compounds of the formula, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS
申请人:Ahmed Gulzar
公开号:US20090221555A1
公开(公告)日:2009-09-03
The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R
1
, R
2
, R
3
, R
4
, R
5
, A
1
, A
2
, A
3
, A
4
, and A
5
, are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.
Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors
申请人:Ahmed Gulzar
公开号:US20120165519A1
公开(公告)日:2012-06-28
The present invention provides a compound of formula I or II
or a pharmaceutically acceptable salt form thereof, wherein R
1
, R
2
, R
3
, R
4
, R
5
, A
1
, A
2
, A
3
, A
4
, and A
5
, are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.
Compounds of the form
In which Q is selected from —CH═NR
12
, —W, —CH
2
NHR
13
, —CH═O and —CH(OR
17
)
2
capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer and formulations and methods of use of such compounds.